Solventum Corporation (SOLV) fair value analysis
S&P 500 · Updated 2026-09-07
Solventum Corporation is a healthcare company that develops, manufactures, and sells medical devices, software, and services for various healthcare applications. The company operates globally, serving customers across North America, Europe, Asia Pacific, and other international markets.
Forward Fair Value verdict
OvervaluedBased on TickrTrends' weekly Forward Fair Value model, SOLV is trading at a 10–25% premium to estimated fair value.
SOLV currently ranks #87 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 2 consecutive weekly runs.
- Last price
- $91.69
- Sector
- Healthcare
- 12-month range
- $64.35–$90.95
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- F
- Leverage
- High
- Margin trend
- Contracting
- Revenue growth
- Modest
- RSI zone
- Neutral
- 52-week position
- The top quarter of its range
What our data shows for SOLV
- Our model validated 8 trailing price-to-earnings windows for SOLV, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $64.35–$90.95.
- The 14-day relative strength index sits at a neutral 59.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for SOLV
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
What people are saying
Follow the SOLV conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — SOLV is a healthcare sector company currently trading at an overvalued level according to TickrTrends' derived indicators. The stock's momentum indicator changed from A-rated to none this week, while its valuation verdict shifted from fairly valued to overvalued. These changes suggest a pullback in positive momentum paired with deteriorating valuation metrics.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is SOLV stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), SOLV is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is SOLV's TickrTrends verdict?
SOLV's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does SOLV compare to other Healthcare stocks?
SOLV ranks #87 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.
Is SOLV overbought or oversold?
SOLV's 14-day RSI is in neutral territory - neither overbought nor oversold.
More in Healthcare
Head-to-head comparisons
SOLV vs ABBV · SOLV vs BIIB · SOLV vs BIO · SOLV vs BVS · SOLV vs CVS